Affordable Access

deepdyve-link
Publisher Website

Donor-specific antibodies in liver transplantation.

Authors
  • Vionnet, Julien1
  • Sempoux, Christine2
  • Pascual, Manuel3
  • Sánchez-Fueyo, Alberto4
  • Colmenero, Jordi5
  • 1 Institute of Liver Studies, King's College Hospital, London, United Kingdom; Transplantation Centre, University Hospital of Lausanne, Lausanne, Switzerland; Service of Gastroenterology and Hepatology, University Hospital of Lausanne, Lausanne, Switzerland. Electronic address: [email protected] , (Switzerland)
  • 2 Institute of Pathology, University Hospital of Lausanne, Lausanne, Switzerland. , (Switzerland)
  • 3 Transplantation Centre, University Hospital of Lausanne, Lausanne, Switzerland. , (Switzerland)
  • 4 Institute of Liver Studies, King's College Hospital, London, United Kingdom. , (United Kingdom)
  • 5 Hospital Clinic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain. , (Spain)
Type
Published Article
Journal
Gastroenterologia y hepatologia
Publication Date
Dec 03, 2019
Identifiers
DOI: 10.1016/j.gastrohep.2019.09.010
PMID: 31810796
Source
Medline
Keywords
Language
Spanish
License
Unknown

Abstract

Despite unique immunoregulatory properties pointing toward tolerance, the liver allograft can be negatively impacted by humoral alloreactivity, with immediate as well as long-term harmful consequences. With regard to the unmet need of long-term outcomes improvement after liver transplantation, donor-specific antibodies have recently been the matter of intense study in this context. We review here recent advances regarding the understanding of the impact of preformed as well as de novo anti-human leukocyte antigen donor-specific antibodies in liver transplantation and discuss potential strategies to overcome this problem. Copyright © 2019 Elsevier España, S.L.U. All rights reserved.

Report this publication

Statistics

Seen <100 times